AUTHOR=Wang Changfeng , Sun Jiali , Guo Lei , Song Dan , Zhang Xin , Liu Zhuang , Wang Liang 

TITLE=Low-dose sclerotherapy with lauromacrogol in the treatment of infantile hemangiomas: A retrospective analysis of 368 cases

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014465

DOI=10.3389/fonc.2022.1014465

ISSN=2234-943X

ABSTRACT=Background: Intralesional injection of lauromacrogol has proven to be an efficient treatment method for infantile hemangioma. This study aims to explore a novel injection therapy and evaluate its efficacy and complications.
Methods: The medical records of 464 children with infantile hemangioma who received a lauromacrogol injection from January 2021 to April 2022 were retrospectively analyzed. All patients were reviewed every 4 weeks and assessed according to symptoms and medical records. The patient's age; lesion type, location, size, and thickness; vascular endothelial growth factor level, lesion photographs, ultrasound findings, and complications were recorded.
Results: Among the 464 infants who accepted sclerotherapy with lauromacrogol, 305 (65.7%) achieved excellent hemangioma regression. In total, 114 (24.6%) cases achieved good regression, 36 (7.8%) achieved complete moderate regression, and 9 (1.9%) achieved poor regression. The reported incidence of adverse events was 5.6%, and severe complications were not observed. Before and after three courses of treatment, the median vascular endothelial growth factor levels were 104.12 pg/mL and 28.982 pg/mL, respectively. There was a significant difference between the two groups (P=0.0043).
Conclusions: The results showed that this novel injection therapy is a safe and effective treatment method. The therapy accelerated the regression of infantile hemangiomas without serious complications.